{"id":20643,"date":"2023-03-22T18:31:00","date_gmt":"2023-03-22T10:31:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20643"},"modified":"2025-01-06T18:35:53","modified_gmt":"2025-01-06T10:35:53","slug":"joincare-pharmaceutical-acquires-rights-to-taigens-pa-endonuclease-inhibitor-tg-1000","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20643","title":{"rendered":"Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000"},"content":{"rendered":"\n

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380<\/a>) has announced a licensing agreement with compatriot firm TaiGen Biotechnology Co., Ltd. Under the terms of the agreement, Joincare will take exclusive development, manufacturing, and commercialization rights to TaiGen\u2019s PA endonuclease inhibitor TG-1000, as well as its derivatives, in the Greater China market, which includes Chinese mainland, Hong Kong, and Taiwan.<\/p>\n\n\n\n

Financial and Development Responsibilities<\/strong>
Joincare will pay TaiGen RMB 20 million (USD 2.9 million) in upfront and milestone payments, along with an 11% sales commission fee. The company will be responsible for advancing the clinical study for the drug in China.<\/p>\n\n\n\n

TG-1000: Advantages and Clinical Progress<\/strong>
TG-1000 is being developed to treat uncomplicated patients with acute infection of simple influenza A and B. It has concluded Phase II clinical trials in China, with Phase III trials confirmed and set to commence soon. Existing data indicate that TG-1000 offers several advantages, including rapid onset, long viral inhibition time, good tolerance, and oral administration not affected by food. Additionally, it is not prone to drug resistance and can effectively inhibit both influenza A and B viruses simultaneously.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[676,965,966],"class_list":["post-20643","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-joincare-pharmaceutical","tag-sha-600380","tag-taigen-biotechnology"],"yoast_head":"\nJoincare Pharmaceutical Acquires Rights to TaiGen's PA Endonuclease Inhibitor TG-1000 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with compatriot firm TaiGen Biotechnology Co., Ltd. Under the terms of the agreement, Joincare will take exclusive development, manufacturing, and commercialization rights to TaiGen\u2019s PA endonuclease inhibitor TG-1000, as well as its derivatives, in the Greater China market, which includes Chinese mainland, Hong Kong, and Taiwan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20643\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Joincare Pharmaceutical Acquires Rights to TaiGen's PA Endonuclease Inhibitor TG-1000\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20643\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-22T10:31:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T10:35:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20643#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20643\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000\",\"datePublished\":\"2023-03-22T10:31:00+00:00\",\"dateModified\":\"2025-01-06T10:35:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20643\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Joincare Pharmaceutical\",\"SHA: 600380\",\"TaiGen Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20643#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20643\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20643\",\"name\":\"Joincare Pharmaceutical Acquires Rights to TaiGen's PA Endonuclease Inhibitor TG-1000 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-22T10:31:00+00:00\",\"dateModified\":\"2025-01-06T10:35:53+00:00\",\"description\":\"China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with compatriot firm TaiGen Biotechnology Co., Ltd. Under the terms of the agreement, Joincare will take exclusive development, manufacturing, and commercialization rights to TaiGen\u2019s PA endonuclease inhibitor TG-1000, as well as its derivatives, in the Greater China market, which includes Chinese mainland, Hong Kong, and Taiwan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20643#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20643\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20643#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Joincare Pharmaceutical Acquires Rights to TaiGen's PA Endonuclease Inhibitor TG-1000 - Insight, China's Pharmaceutical Industry","description":"China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with compatriot firm TaiGen Biotechnology Co., Ltd. Under the terms of the agreement, Joincare will take exclusive development, manufacturing, and commercialization rights to TaiGen\u2019s PA endonuclease inhibitor TG-1000, as well as its derivatives, in the Greater China market, which includes Chinese mainland, Hong Kong, and Taiwan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20643","og_locale":"en_US","og_type":"article","og_title":"Joincare Pharmaceutical Acquires Rights to TaiGen's PA Endonuclease Inhibitor TG-1000","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20643","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-22T10:31:00+00:00","article_modified_time":"2025-01-06T10:35:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20643#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20643"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000","datePublished":"2023-03-22T10:31:00+00:00","dateModified":"2025-01-06T10:35:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20643"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Joincare Pharmaceutical","SHA: 600380","TaiGen Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20643#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20643","url":"https:\/\/flcube.com\/?p=20643","name":"Joincare Pharmaceutical Acquires Rights to TaiGen's PA Endonuclease Inhibitor TG-1000 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-22T10:31:00+00:00","dateModified":"2025-01-06T10:35:53+00:00","description":"China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with compatriot firm TaiGen Biotechnology Co., Ltd. Under the terms of the agreement, Joincare will take exclusive development, manufacturing, and commercialization rights to TaiGen\u2019s PA endonuclease inhibitor TG-1000, as well as its derivatives, in the Greater China market, which includes Chinese mainland, Hong Kong, and Taiwan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20643#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20643"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20643#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20643"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20643\/revisions"}],"predecessor-version":[{"id":20645,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20643\/revisions\/20645"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}